青少年及成人先天性免疫缺陷病的造血干细胞移植:一项EBMT IEWP研究
这项大型回顾性多中心研究分析了2000至2019年间接受首次异基因造血干细胞移植的329例先天性免疫缺陷病患者(移植时年龄15至62.5岁),中位随访44.3个月时1年和5年总生存率分别为78%和71%,无事件生存率分别为65%和62%,严重急性移植物抗宿主病发生率为8%,广泛性慢性移植物抗宿主病为7%。
要点
- 移植时年龄15至62.5岁的先天性免疫缺陷病患者1年和5年总生存率分别为78%和71%。
- 1年和5年无事件生存率分别为65%和62%,严重急性移植物抗宿主病发生率8%,广泛性慢性移植物抗宿主病7%。
- 多因素分析显示先天性免疫缺陷相关并发症数量较多者无事件生存率较差,年龄和供者类型对生存无显著影响。
核心结论
- 研究识别出不依赖于年龄的不良结局危险因素,为判断哪些患者最可能从造血干细胞移植中获益提供了证据。
研究设计与样本
- 大型回顾性多中心造血干细胞移植结局研究,纳入329例先天性免疫缺陷病患者,移植时年龄范围15至62.5岁,患者于2000年至2019年间接受首次造血干细胞移植。
- 主要终点为总生存率和无事件生存率,同时评估先天性免疫缺陷亚组及移植时先天性免疫缺陷相关危险因素的影响。
主要发现
- 中位随访44.3个月时,全部患者移植后1年和5年总生存率分别为78%和71%,无事件生存率分别为65%和62%。
- 严重急性移植物抗宿主病发生率为8%,广泛性慢性移植物抗宿主病发生率为7%。
- 单因素分析显示,原发性抗体缺陷、支气管扩张、既往脾切除、肝脏合并症及较高的造血干细胞移植合并症指数评分患者的总生存率和无事件生存率较差。
- 多因素分析显示,先天性免疫缺陷相关并发症数量较多者的无事件生存率较差。
- 年龄和供者类型对总生存率和无事件生存率均无显著影响。
关键数值与推荐
- 全部患者移植后1年总生存率为78%,5年总生存率为71%。
- 全部患者移植后1年无事件生存率为65%,5年无事件生存率为62%。
- 严重急性移植物抗宿主病发生率为8%,广泛性慢性移植物抗宿主病发生率为7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (HSCT) is the gold standard curative therapy for infants and children with many inborn errors of immunity (IEI), but adolescents and adults with IEI are rarely referred for transplant. Lack of published HSCT outcome data outside small, single-center studies and perceived high risk of transplant-related mortality have delayed the adoption of HSCT for IEI patients presenting or developing significant organ damage later in life. This large retrospective, multicenter HSCT outcome study reports on 329 IEI patients (age range, 15-62.5 years at HSCT). Patients underwent first HSCT between 2000 and 2019. Primary endpoints were overall survival (OS) and event-free survival (EFS). We also evaluated the influence of IEI-subgroup and IEI-specific risk factors at HSCT, including infections, bronchiectasis, colitis, malignancy, inflammatory lung disease, splenectomy, hepatic dysfunction, and systemic immunosuppression. At a median follow-up of 44.3 months, the estimated OS at 1 and 5 years post-HSCT for all patients was 78% and 71%, and EFS was 65% and 62%, respectively, with low rates of severe acute (8%) or extensive chronic (7%) graft-versus-host disease. On univariate analysis, OS and EFS were inferior in patients with primary antibody deficiency, bronchiectasis, prior splenectomy, hepatic comorbidity, and higher hematopoietic cell transplant comorbidity index scores. On multivariable analysis, EFS was inferior in those with a higher number of IEI-associated complications. Neither age nor donor had a significant effect on OS or EFS. We have identified age-independent risk factors for adverse outcome, providing much needed evidence to identify which patients are most likely to benefit from HSCT.
引用
- Albert MH, Sirait T, Eikema DJ, et al. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study. Blood. 2022. PMID: 35344580. doi:10.1182/blood.2022015506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。